Clinical Center, Maryland
Supplementary Table.
Comparisons of clinical signs and symptoms, myositis autoantibodies and local complications associated with the use of silicone implants between MASI patients and matched IIM or SIC study groups.
| Clinical Signs / Symptoms | MASI, n=26 n (%) | IIM, n=52 n (%) |
|---|---|---|
| Fatigue | 26 (100) | 14 (26.9) |
| Weight Loss | 11 (42.3) | 19 (36.5) |
| Fatigue | 26 (100) | 47 (90.4) |
| Raynaud's Sign | 11 (42.3) | 25 (48.1) |
| Sjogren's Syndrome | 15 (57.7) | 19 (36.5) |
| Proximal Weakness | 26 (100) | 46 (88.5) |
| Distal Weakness | 12 (46.2) | 19 (36.5) |
| Asymmetric Weakness | 5 (19.2) | 14 (26.9) |
| Muscle Cramps | 9 (34.6) | 21 (40.4) |
| Arthralgias | 19 (73.1) | 24 (46.2) |
| Arthritis | 14 (53.8) | 19 (36.5) |
| Falling | 5 (19.2) | 13 (25.0) |
| Muscle Atrophy | 6 (23.1) | 19 (36.5) |
| Contractures | 3 (11.5) | 4 (7.7) |
| Carpel Tunnel | 4 (15.4) | 10 (19.2) |
| Dyspnea (EX) | 16 (61.5) | 20 (38.5) |
| Dyspnea (RE) | 7 (26.9) | 9 (17.3) |
| O2 Use | 4 (15.4) | 6 (11.2) |
| Changes Pulmonary Funct. | 7 (26.9) | 9 (17.3) |
| Interstitial Lung Disease | 8 (30.8) | 11 (21.2) |
| Cough | 5 (19.2) | 11 (21.2) |
| Chest Pain | 2 (7.7) | 5 (9.6) |
| Palpitation | 5 (19.2) | 15 (28.8) |
| Edema | 13 (50.0) | 16 (30.8) |
| Syncope | 0 (0) | 2 (3.8) |
| Dysphagia | 12 (46.2) | 24 (46.2) |
| Regurgitation | 5 (19.2) | 7 (13.5) |
| Diarrhea | 2 (7.7) | 6 (11.2) |
| Heliotrope Rash | 9 (34.6) | 19 (36.5) |
| V Sign Rash | 5 (19.2) | 10 (19.2) |
| Shawl Sign Rash | 3 (11.5) | 12 (23.1) |
| Gottron's Papules | 10 (38.5) | 17 (32.7) |
| Other Rashes | 4 (15.4) | 17 (32.7) |
| Mechanic's Hands | 4 (15.4) | 7 (13.5) |
| Nailbed Changes | 4 (15.4) | 6 (11.2) |
| Cuticular Overgrowth | 3 (11.5) | 6 (11.2) |
| Lymphadenopathy | 3 (11.5) | 1 (1.9) |
| Myositis-Specific Autoantibodies (MSA) | MASI, n=26 n (%) | IIM, n=51** n (%) |
|---|---|---|
| MSA | 8 (30.8) | 22 (43.1) |
| Synthetase | 5 (19.2) | 18 (35.3) |
| Jo-1 | 3 (11.5) | 14 (27.5) |
| THR | 1 (3.8) | 3 (5.9) |
| ILE | 1 (3.8) | 1 (2.0) |
| Mi-2 | 2 (7.7) | 3 (5.9) |
| SRP | 1 (3.8) | 1 (2.0) |
| Myositis-Associated Autoantibodies (MAA) | MASI, n=26 n (%) | IIM, n=51** n (%) |
|---|---|---|
| MAA | 6 (23.1) | 16 (31.4) |
| KU | 0 (0) | 0 (0) |
| LA | 0 (0) | 5 (9.8) |
| RO | 3 (11.5) | 6 (11.8) |
| PM/Scl | 0 (0) | 1 (2.0) |
| SM | 0 (0) | 2 (3.9) |
| RNP | 3 (11.5) | 2 (3.9) |
| Local Complications | MASI, n=26 n (%) | SIC, n=52** n (%) |
|---|---|---|
| Contracture | 12 (46.2) | 29 (55.8) |
| Rupture | 8 (30.8) | 18 (34.6) |
| Pain | 6 (23.1) | 11 (21.2) |
| Infection | 3 (11.5) | 5 (9.6) |
| Bleeding | 0 (0) | 7 (13.5) |
| Lumps/Asymmetry | 7 (26.9) | 9 (17.3) |
| LNE | 4 (15.4) | 8 (15.4) |
| Explants | 17 (65.4) | 28 (53.8) |
* Abbreviations per manuscript Table 1 and Jo-1, anti-histidyl tRNA synthetase; THR, anti-threonyl tRNA synthetase; ILE, anti-isoleucyl tRNA synthetase; Mi-2, anti-Mi-2; SRP, anti-signal recognition particle; LNE, lymph node enlargement. There were no significant differences (after correction for multiple comparisons) regarding these data among the groups.
**Serum was unavailable for 1 of 52 IIM patients.